NASDAQ:GNTA - Genenta Science Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $21.00
  • Forecasted Upside: 154.55 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$8.25
▲ +0.72 (9.56%)

This chart shows the closing price for GNTA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Genenta Science Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GNTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GNTA

Analyst Price Target is $21.00
▲ +154.55% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Genenta Science in the last 3 months. The average price target is $21.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 154.55% upside from the last price of $8.25.

This chart shows the closing price for GNTA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Genenta Science.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/27/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/28/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/28/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/13/2022Maxim GroupInitiated CoverageBuy$21.00Low
1/12/2022Roth CapitalReiterated RatingBuyN/A
(Data available from 5/28/2017 forward)

News Sentiment Rating

-0.69 (Sell)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/29/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/28/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
2/27/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/29/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/28/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 5 very negative mentions
5/28/2022

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 5 very negative mentions
Genenta Science logo
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon and other immune-gene therapy programs for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
Read More

Today's Range

Now: $8.25
Low: $7.50
High: $8.30

50 Day Range

MA: $6.40
Low: $5.39
High: $8.25

52 Week Range

Now: $8.25
Low: $5.11
High: $13.13

Volume

13,695 shs

Average Volume

10,074 shs

Market Capitalization

$150.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Genenta Science?

The following Wall Street analysts have issued reports on Genenta Science in the last year: Maxim Group, Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for GNTA.

What is the current price target for Genenta Science?

0 Wall Street analysts have set twelve-month price targets for Genenta Science in the last year. Their average twelve-month price target is $21.00, suggesting a possible upside of 154.5%.
View the latest price targets for GNTA.

What is the current consensus analyst rating for Genenta Science?

Genenta Science currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GNTA will outperform the market and that investors should add to their positions of Genenta Science.
View the latest ratings for GNTA.

How do I contact Genenta Science's investor relations team?

The company's listed phone number is 39-02-2643-6639 and its investor relations email address is [email protected] The official website for Genenta Science is www.genenta.com. Learn More about contacing Genenta Science investor relations.